Navigation Links
Data Presented For ENMD-2076 In Preclinical Models Of Triple-Negative Breast Cancer
Date:10/21/2013

clinical applications. Taken together, we believe they will shed additional light on more advanced clinical trials and enhance the value of ENMD-2076."  

To view the poster presentation, visit the Company's website at http://www.entremed.com.

About ENMD-2076
ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action.  ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase.  Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers.  ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers.  ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, multiple myeloma, and is currently completing a Phase 2 trial for ovarian cancer.  EntreMed is currently conducting a Phase 2 study of ENMD-2076 in triple-negative breast cancer, a Phase 2 study in advanced/metastatic soft tissue sarcoma, and expecting to initiate a Phase 2 study in ovarian clear cell carcinoma.  ENMD-2076 has received orphan drug designation from the FDA for the treatment of ovarian cancer, multiple myeloma and acute myeloid leukemia.

About EntreMed
EntreMed is a clinical-stage pharmaceutical company employing a drug development strategy primarily in the United States and China to develop targeted therapeutics for the global market.  Its lead compound, ENMD-2076, a selective angiogenic kinase inhibitor, has completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia, and is currently completing a multi-center Phase 2 study in ovarian cancer.  EntreMed is currently conducting a Phase 2 stud
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Additional Results of Global Primary Biliary Cirrhosis Study Group Analysis to be Presented at AASLD Annual Meeting
2. Pivotal Phase 3 Data from Boehringer Ingelheim Hepatitis C Portfolio to be Presented at 64th Annual AASLD Meeting
3. Simeprevir Data in Hepatitis C Patients to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
4. Data Presented at 49th EASD Annual Meeting Show Treatment with Lillys Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes
5. Anthera Pharmaceuticals Announces Emerging Data from Phase 2 Open-Label Extension Study to be Presented at the ACR/ARHP 2013 Annual Scientific Meeting
6. Data From Post-Hoc Analyses Presented at EASD Examine Safety Profile of Linagliptin in Adults with Type 2 Diabetes
7. Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials to be Presented at the 2013 San Antonio Breast Cancer Conference
8. LipoScience Announces Data Presented at the 2013 American Diabetes Association Meeting
9. New data about the safety and efficacy of linagliptin in adults with type 2 diabetes who have moderate to severe renal impairment presented at ADA
10. Ibrutinib Monotherapy Clinical Trial Data in Patients with Waldenstroms Macroglobulinemia Presented at the International Conference on Malignant Lymphoma in Lugano, Switzerland
11. Safinamide Phase III Study Results Presented at 2013 MDS Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , July 20, 2015 Research ... addition of the "Key Pharma News Issue" ... This acquisition bolsters Gilead Sciences, burgeoning oncology pipeline ... will make further oncology deals in 2015, with ... of 2016. Key Pharma News ...
(Date:7/27/2015)... Belgium , July 27, 2015 /PRNewswire/ ... life sciences company focused on developing blood-based diagnostic tests ... conditions, today announced that it has engaged the services ... Specimen Solutions, Inc. (GSS), to support initial U.S. market ... Under the agreement, GSS will target ...
(Date:7/27/2015)... , July 27, 2015 Syneron ... ) , a global market leader in the aesthetic ... Korean Ministry of Food and Drug Safety (MFDS) regulatory ... clearance, the Company can fulfill PicoWay orders from its ... Korea anticipated later in the third quarter 2015. ...
Breaking Medicine Technology:Key Pharma News Issue - Gilead will make further oncology deals in 2015 2Key Pharma News Issue - Gilead will make further oncology deals in 2015 3VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 2VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 3VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 4VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 5VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 6VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 7Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 2Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 3Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 4
... Interventional Radiology Treatment Relieves Pain From Herniated Disks; ... but With Fewer Complications, Shorter Recovery TimeSAN DIEGO, ... treatment--that safely and effectively uses oxygen/ozone to relieve ... the United States in the next few years, ...
... Minimally Invasive "Lumpectomy" -- as Effective as Surgery -- ... Mapping Biopsy Changed Patients, Management 70 Percent of the ... -- a minimally invasive interventional radiology treatment for prostate ... diseased tumors and can be considered a first-line treatment ...
Cached Medicine Technology:Oh, My Aching Back: Give Me a Shot of Ozone 2Oh, My Aching Back: Give Me a Shot of Ozone 3Oh, My Aching Back: Give Me a Shot of Ozone 4Oh, My Aching Back: Give Me a Shot of Ozone 5Freezing Prostate Cancer Does a Man's Body Good 2Freezing Prostate Cancer Does a Man's Body Good 3Freezing Prostate Cancer Does a Man's Body Good 4Freezing Prostate Cancer Does a Man's Body Good 5Freezing Prostate Cancer Does a Man's Body Good 6Freezing Prostate Cancer Does a Man's Body Good 7
(Date:7/27/2015)... ... July 28, 2015 , ... Conducting Advanced Root ... to Improve the Quality of Investigations , **Presented by FDAnews and Learning Plus**, ... CAPAs have been the #1 reason for 483 observations since 1997! , The ...
(Date:7/27/2015)... NY (PRWEB) , ... July 28, 2015 , ... ... a 2015-2016 inductee into the NAPW VIP Woman of the Year Circle. She is ... and over 200 operating Local Chapters, NAPW is the nation’s leading networking organization exclusively ...
(Date:7/27/2015)... ... July 27, 2015 , ... ... science of the little-known and incurable disease, facioscapulohumeral muscular dystrophy (FSHD), today announced ... of Neurology (AAN). The FSHD care guideline is published today. , This ...
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... North Central ... 2015. , The center invites all those prospective joint-replacement patients, along with their ... Thursday of each month, with Monday classes (Aug 6, Sept 8 [Tue due to ...
(Date:7/27/2015)... ... July 27, 2015 , ... ... is a professional and in-depth research report. The report provides basic information ... market analysis etc. This report covers the global (US, Europe, Japan etc) ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 16-17, 2015, Raleigh, NC 2Health News:FDAnews Announces: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 16-17, 2015, Raleigh, NC 3Health News:FDAnews Announces: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 16-17, 2015, Raleigh, NC 4Health News:NAPW Inducts Jane Simmons, Counseling Intern at Omar Bradley Middle School of the Northeast Independent School District , Into its VIP Woman of the Year Circle 2Health News:First-Ever FSHD Evidence-based Care Guideline Published by the American Academy of Neurology 2Health News:North Central Surgical Center Hospital to Hold Joint Wellness Classes 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 3
... Address FDA,s Next Big Challenge, Is the Food ... Devices to Physicians and the Public?, WASHINGTON, Nov. ... device that repairs damaged cells and treats cancer through,electromagnetic ... its apparent connection to patient injuries and death. However,on ...
... - The Westaim Corporation,announced today that it has reached ... in Canadian third party asset-backed commercial paper (ABCP) with,a ... $6.0 million.,Westaim retains the right to receive additional proceeds ... six months; in such event, Westaim,will receive 50 per ...
... (Nasdaq: FLEX ),today announced that it will report ... earnings conference call, hosted by Flextronics,s senior,management, will be ... results,of the Company for its third quarter ended December ... via the Internet and may be,accessed by logging on ...
... may be undertreated compared to white patients, research suggests , ... likely than white women to suffer severe pain linked to ... than 1,100 patients in 19 countries. , The women -- ... given a pain test called the Brief Pain Inventory repeatedly ...
... Kocot and Robert,Seidman Headline Agenda at FDA/CMS Summit ... has,progressed beyond a topic of industry insider buzz ... and private payers. Value isn,t a new,concept in ... for buying and,selling biopharmaceuticals? How is value calculated, ...
... Nov. 26 Pharmasset, Inc.,(Nasdaq: VRUS ) ... & Sales, responsible for coordinating the global product ... Higgins, who,has served as a consultant to Pharmasset ... Virology at Hoffmann-LaRoche, Inc. His areas,of expertise include ...
Cached Medicine News:Health News:Food and Drug Law Institute Sponsors Colloquium on Communicating Risk/Safety Drug Information 2Health News:Westaim reduces ABCP exposure 2Health News:Flextronics to Report Third Quarter Results 2Health News:Defining the Value of Medicine in an Evidence-Based Healthcare Marketplace 2Health News:Defining the Value of Medicine in an Evidence-Based Healthcare Marketplace 3Health News:Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales 2Health News:Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales 3
Inquire...
Glucose tubes contain an anti-coagulant and a stabiliser. The tubes are ideal for glucose and lactate determinations....
BD Vacutainer® Fluoride Tubes - Glass...
VACUETTE Trace Element tubes - Ridged (safety screw cap) are designed to test trace elements such as Cu, Zn, Pb, etc....
Medicine Products: